Main Sequence Ventures

Main Sequence Ventures occupies a distinct position in the Australian venture market: it was established with backing from CSIRO, the country’s national science agency, and operates with a mandate to commercialize Australian research alongside its independent venture activity. That dual identity shapes both its sourcing, which leans toward research-heavy companies, and its operating style, which is unusually patient with deep-tech timelines.

The healthcare focus runs through deep tech, biotech, and AI/ML in healthcare. Within that, Main Sequence has been active with synthetic biology companies, biotech platforms commercializing Australian academic research, and AI work applied to clinical, agricultural, and industrial life-science problems. The fund is comfortable backing companies whose underlying science is genuinely novel and whose commercial paths require multi-year development. AI is treated as a layer present in nearly every modern science-driven company rather than as a sub-vertical in its own right.

Check sizes run from $1M to $5M across seed, Series A, and Series B. That positioning makes Main Sequence a natural lead or co-lead in early institutional rounds for Australian research spinouts and a meaningful participant in follow-on rounds as portfolio companies scale. Founders should expect diligence that engages with the underlying science, IP, and regulatory pathways alongside commercial questions, and they should expect the fund to be honest about the timelines and capital requirements of deep-tech companies.

The team brings investing, operating, and scientific backgrounds, with relationships across Australian universities, research institutions, and CSIRO itself. Those relationships are a meaningful part of what the fund offers, particularly for companies whose progression depends on access to research infrastructure, scientific advisors, or government and corporate partners. The fund is comfortable working with first-time founders coming out of academic environments and with management teams that combine scientific depth with experienced commercial operators.

For founders, working with Main Sequence means an investor that takes the science seriously, engages on strategic and operational questions, and is willing to be patient with development timelines. Post-investment support tends to focus on follow-on syndication including with US and European co-investors, scientific advisor and customer introductions, and helping companies navigate the practical complexity of building globally competitive science companies from an Australian base. The fund is a less natural fit for software-only companies without meaningful technical depth or for founders who want a fast, momentum-driven fundraising process. It is a strong fit for scientifically credible Australian teams whose ambitions are global and who want an investor with the patience, the scientific literacy, and the network to support a multi-year path from research to product. Main Sequence’s tone with founders tends to be candid and substantive.